SG170735A1 - Process for preparing oxycodone hydrochloride having less than 25 ppm 14- hydroxycodeinone - Google Patents

Process for preparing oxycodone hydrochloride having less than 25 ppm 14- hydroxycodeinone

Info

Publication number
SG170735A1
SG170735A1 SG201101931-2A SG2011019312A SG170735A1 SG 170735 A1 SG170735 A1 SG 170735A1 SG 2011019312 A SG2011019312 A SG 2011019312A SG 170735 A1 SG170735 A1 SG 170735A1
Authority
SG
Singapore
Prior art keywords
hydroxycodeinone
ppm
less
oxycodone hydrochloride
preparing oxycodone
Prior art date
Application number
SG201101931-2A
Other languages
English (en)
Inventor
Robert Chapman
Lonn S Rider
Qi Hong
Donald Kyle
Robert Kupper
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35124996&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG170735(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of SG170735A1 publication Critical patent/SG170735A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG201101931-2A 2004-03-30 2005-03-30 Process for preparing oxycodone hydrochloride having less than 25 ppm 14- hydroxycodeinone SG170735A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US55749204P 2004-03-30 2004-03-30
US60153404P 2004-08-13 2004-08-13
US62007204P 2004-10-18 2004-10-18
US64862505P 2005-01-31 2005-01-31
US65177805P 2005-02-10 2005-02-10

Publications (1)

Publication Number Publication Date
SG170735A1 true SG170735A1 (en) 2011-05-30

Family

ID=35124996

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201406658VA SG10201406658VA (en) 2004-03-30 2005-03-30 Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
SG201101931-2A SG170735A1 (en) 2004-03-30 2005-03-30 Process for preparing oxycodone hydrochloride having less than 25 ppm 14- hydroxycodeinone
SG201101934-6A SG170736A1 (en) 2004-03-30 2005-03-30 Process for preparing oxycodone hydrochloride having less than 25 ppm 14- hydroxycodeinone

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201406658VA SG10201406658VA (en) 2004-03-30 2005-03-30 Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG201101934-6A SG170736A1 (en) 2004-03-30 2005-03-30 Process for preparing oxycodone hydrochloride having less than 25 ppm 14- hydroxycodeinone

Country Status (39)

Country Link
US (35) US7129248B2 (zh)
EP (7) EP2426132B1 (zh)
JP (8) JP4912294B2 (zh)
KR (12) KR20150046393A (zh)
CN (5) CN1960994B (zh)
AP (1) AP2232A (zh)
AR (1) AR049012A1 (zh)
AT (2) ATE501150T1 (zh)
AU (2) AU2005230826C1 (zh)
BR (1) BRPI0508758B8 (zh)
CA (3) CA2774121C (zh)
CR (2) CR8593A (zh)
CY (5) CY1111487T1 (zh)
DE (2) DE202005021371U1 (zh)
DK (6) DK2319846T3 (zh)
EA (1) EA013208B1 (zh)
EC (1) ECSP066953A (zh)
ES (6) ES2585576T3 (zh)
FI (1) FI7843U1 (zh)
HK (3) HK1098745A1 (zh)
HR (5) HRP20110425T4 (zh)
HU (3) HUE029913T2 (zh)
IL (8) IL178038A (zh)
LT (2) LT2316837T (zh)
MA (1) MA28492B1 (zh)
ME (4) ME03068B (zh)
MX (2) MX363228B (zh)
MY (3) MY172063A (zh)
NO (1) NO337669B1 (zh)
NZ (3) NZ601326A (zh)
PE (1) PE20050880A1 (zh)
PL (5) PL1730151T5 (zh)
PT (5) PT1730151E (zh)
RS (5) RS57000B1 (zh)
SG (3) SG10201406658VA (zh)
SI (5) SI2426132T1 (zh)
TW (3) TWI483944B (zh)
WO (1) WO2005097801A1 (zh)
ZA (1) ZA200607181B (zh)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
PT1842533E (pt) * 2003-08-06 2013-05-17 Gruenenthal Gmbh Forma de dosagem protegida contra abuso
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
TWI483944B (zh) 2004-03-30 2015-05-11 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
GB0421149D0 (en) * 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
ME01594B (me) * 2005-03-04 2014-09-20 Euro Celtique Sa Postupak smanjenja alfa, beta nezasićenih ketona u opioidnim kompozicijama
WO2007011819A2 (en) * 2005-07-15 2007-01-25 The Penn State Research Foundation Ferritin as a therapeutic target in abnormal cells
US7875623B2 (en) * 2005-11-22 2011-01-25 Controlled Chemicals, Inc. Process for reducing contaminating Michael acceptor levels in oxycodone and other compositions
US20070117826A1 (en) * 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
CN101395159A (zh) * 2006-03-02 2009-03-25 马林克罗特公司 制备含有低含量α,β-不饱和酮化合物的吗啡烷-6-酮产物的方法
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US20080125592A1 (en) * 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
CA2674915C (en) * 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
WO2008048711A1 (en) * 2006-10-17 2008-04-24 Penick Corporation Process for preparing oxymorphone
US7906647B2 (en) 2006-12-04 2011-03-15 Noramco, Inc. Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone
AU2007329451B2 (en) * 2006-12-04 2012-08-30 Noramco, Llc Process for reducing impurities in oxycodone base
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
CA2681740A1 (en) * 2007-03-23 2008-10-02 Mallinckrodt Inc. Improved preparation of oxymorphone from oripavine
CA2684458A1 (en) * 2007-04-16 2008-10-30 Mallinckrodt Inc. Novel opiate reduction utilizing catalytic hydrogen transfer reaction
TWI454288B (zh) 2008-01-25 2014-10-01 Gruenenthal Chemie 藥物劑型
MX2010009990A (es) * 2008-03-11 2010-12-15 Depomed Inc Formas de dosificación gástricas retentivas de liberación prolongada que comprenden combinaciones de un analgésico no opioide y un analgésico opioide.
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
PT2273983T (pt) 2008-05-09 2016-10-28 Gruenenthal Gmbh Processo para a preparação de uma formulação em pó intermediária e uma forma de dosagem sólida final sob utilização de uma etapa de congelamento por atomização
CA2737257C (en) * 2008-09-18 2016-11-15 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly(.epsilon.-caprolactone)
CN102573805A (zh) * 2009-07-22 2012-07-11 格吕伦塔尔有限公司 热熔挤出的控制释放剂型
ES2560210T3 (es) * 2009-07-22 2016-02-17 Grünenthal GmbH Forma de dosificación resistente a la manipulación para opiádes sensibles a la oxidación
RU2012112552A (ru) * 2009-08-31 2013-10-10 Дипомед, Инк. Удерживаемые в желудке фармацевтические композиции для немедленного и продленного высвобождения ацетаминофена
CA2775890C (en) 2009-09-30 2016-06-21 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
CN102821757B (zh) * 2010-02-03 2016-01-20 格吕伦塔尔有限公司 通过挤出机制备粉末状药物组合物
EP2377866B1 (en) 2010-03-23 2014-02-26 Siegfried AG Preparation of low impurity opiates in a continuous flow reactor
US9901540B2 (en) 2010-05-10 2018-02-27 Euro-Celtique S.A. Combination of active loaded granules with additional actives
CN102946870A (zh) 2010-05-10 2013-02-27 欧洲凯尔特公司 包含氢吗啡酮和纳洛酮的药物组合物
EP2568968B1 (en) 2010-05-10 2017-07-12 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
EP2580218B1 (en) 2010-06-11 2015-02-25 Rhodes Technologies Process for n-dealkylation of tertiary amines
ES2645725T3 (es) 2010-06-11 2017-12-07 Rhodes Technologies Procesos catalizados por metales de transición para la preparación de compuestos de N-alilo y uso de los mismos
CA2804101C (en) 2010-07-02 2021-01-19 Johnson Matthey Public Limited Company Process for the synthesis and purification of oxycodone
US8912781B2 (en) * 2010-07-30 2014-12-16 Cirrus Logic, Inc. Integrated circuit switching power supply controller with selectable buck mode operation
TWI516286B (zh) 2010-09-02 2016-01-11 歌林達股份有限公司 含陰離子聚合物之抗破碎劑型
RU2604676C2 (ru) 2010-09-02 2016-12-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
LT2736495T (lt) 2011-07-29 2017-11-10 Grünenthal GmbH Sugadinimui atspari tabletė, pasižyminti greitu vaisto atpalaidavimu
CN103857386A (zh) 2011-07-29 2014-06-11 格吕伦塔尔有限公司 提供药物立即释放的抗破碎片剂
WO2013034273A1 (en) * 2011-09-05 2013-03-14 Siegfried Ltd. Kit comprising a packaging material and a solid pharmaceutical or nutraceutical product contained in the packaging material
CA2847611A1 (en) 2011-09-16 2013-03-21 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
WO2013038268A1 (en) 2011-09-16 2013-03-21 Purdue Pharma L.P. Tamper resistant immediate release formulations
EP2787978B1 (en) 2011-12-09 2016-09-21 Purdue Pharma LP Pharmaceutical dosage forms comprising poly(epsilon-caprolactone) and polyethylene oxide
JP6117249B2 (ja) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
CN109820830A (zh) 2012-03-02 2019-05-31 罗德兹制药股份有限公司 抗破坏性立即释放型制剂类
CA3120681C (en) 2012-04-17 2024-05-28 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CA2868142A1 (en) 2012-04-18 2013-10-24 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
PL2872121T3 (pl) 2012-07-12 2019-02-28 SpecGx LLC Kompozycje farmaceutyczne o przedłużonym uwalnianiu, zniechęcające do nadużywania
TWI588147B (zh) 2012-07-16 2017-06-21 羅德科技公司 改良之類鴉片合成方法
SG11201407988UA (en) 2012-07-16 2015-01-29 Rhodes Technologies Process for improved opioid synthesis
HUE042762T2 (hu) * 2012-08-03 2019-07-29 Johnson Matthey Plc Eljárás oxikodon elõállítására
MX366159B (es) 2012-11-30 2019-07-01 Acura Pharmaceuticals Inc Liberacion autorregulada de ingrediente farmaceutico activo.
EA201500742A1 (ru) 2013-02-05 2015-12-30 Пердью Фарма Л.П. Защищенные от нецелевого использования фармацевтические композиции
US9770710B2 (en) 2013-02-20 2017-09-26 University Of Washington Through Its Center For Commercialization Hydrogenation and disproportionation catalysis
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
CN105682643B (zh) 2013-07-12 2019-12-13 格吕伦塔尔有限公司 含有乙烯-醋酸乙烯酯聚合物的防篡改剂型
GB201313211D0 (en) 2013-07-24 2013-09-04 Cambrex Karlskoga Ab New process
BR112016002079A2 (pt) 2013-08-02 2017-09-05 Johnson Matthey Plc Processo para preparação de um aditivo ácido de oximorfona, solução aquosa de aditivo ácido de oximorfona, aditivo ácido de oximorfona sólido, e, alcaloide de oximorfona sólido
GB201313915D0 (en) * 2013-08-02 2013-09-18 Johnson Matthey Plc Process
US9193737B2 (en) 2013-11-07 2015-11-24 Mallinckrodt Llc Production of 6-hydroxy morphinans without the isolation of intermediates
WO2015071380A1 (en) 2013-11-13 2015-05-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
US8846923B1 (en) 2013-12-18 2014-09-30 Cody Laboratories, Inc. Preparation of 14-hydroxycodeinone sulfate
US10227354B2 (en) 2013-12-18 2019-03-12 Cody Laboratories, Inc. Conversion of oxycodone base to oxycodone hydrochloride
US9062062B1 (en) 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride
CA2937007C (en) 2014-01-15 2018-11-06 Rhodes Technologies Process for improved oxymorphone synthesis
WO2015107471A1 (en) 2014-01-15 2015-07-23 Rhodes Technologies Process for improved oxycodone synthesis
US10632113B2 (en) 2014-02-05 2020-04-28 Kashiv Biosciences, Llc Abuse-resistant drug formulations with built-in overdose protection
CA2943728C (en) 2014-03-26 2020-03-24 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
CA2954600A1 (en) 2014-07-09 2016-01-14 Rhodes Technologies Reduction of alpha, beta-unsaturated ketone levels in morphinan derivative compositions
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
US20160052932A1 (en) 2014-08-25 2016-02-25 Johnson Matthey Public Limited Company Processes for Making Opioids Including 14-Hydroxycodeinone and 14-hydroxymorphinone
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CN105777766B (zh) * 2014-12-15 2017-11-24 北大方正集团有限公司 Delta‑7溴甲纳曲酮的制备方法
US9918979B2 (en) * 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
CN107889459A (zh) 2015-04-24 2018-04-06 格吕伦塔尔有限公司 具有立即释放和对溶剂萃取的抗性的抗篡改剂型
GB201513203D0 (en) 2015-07-27 2015-09-09 Cambrex Charles City Inc New process
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US20180104236A1 (en) 2016-09-26 2018-04-19 Euro-Celtique S. A. Methods of treatment comprising administering a high daily dose of oxycodone and naloxone in a 2:1 weight ratio
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
EP4122933A1 (en) 2017-06-20 2023-01-25 Johnson Matthey Public Limited Company Hydrogenation process for preparing oxycodone hydrochloride from 14-hydroxycodeinone
CN110330500B (zh) * 2019-07-12 2021-11-23 宜昌人福药业有限责任公司 一种6β-羟基-7,8-二氢-吗啡衍生物的立体选择性合成方法
CN113009060B (zh) * 2021-02-24 2022-10-21 西南药业股份有限公司 高效液相色谱法测定盐酸羟考酮含量的方法

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1468805A (en) 1923-09-25 Htabtin ereund
US105553A (en) 1870-07-19 Improvement in kettle for melting, mixing, and casting metals
US1485673A (en) * 1924-03-04 Ministrator
DE296916C (zh)
DE286431C (zh)
US420098A (en) * 1890-01-28 Mowing-machine
US100000A (en) * 1870-02-22 Improved sun-bonnet for horses
US710223A (en) * 1901-06-10 1902-09-30 Thew Automatic Shovel Company Power-shovel.
SU64699A1 (ru) 1944-01-26 1944-11-30 А.И. Лютенберг Способ получени сол нокислого дигидрооксикодеинона
ES212554A1 (es) 1953-12-01 1954-08-16 Casanovas Albajes Cesar Un procedimiento para la obtención de un vidrio orgánico
US2772270A (en) 1954-10-21 1956-11-27 M J Lewenstein 14-hydroxymorphinone and 8, 14-dihydroxydihydromorphinone
US2806033A (en) 1955-08-03 1957-09-10 Lewenstein Morphine derivative
US3173878A (en) * 1960-02-26 1965-03-16 Ibm Process of making microcapsules
US3173876A (en) * 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (zh) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3916898A (en) 1964-05-20 1975-11-04 Searle & Co Administration of medicaments and the like
NL6714885A (zh) * 1967-11-02 1969-05-06
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3905981A (en) * 1973-10-12 1975-09-16 Research Corp N-dealkylation of tertiary amines
US3894026A (en) 1973-10-16 1975-07-08 Merck & Co Inc Production of thebaine
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US3984026A (en) * 1976-03-26 1976-10-05 Shoup Russel W Combined can opening and sealing device
US4045440A (en) 1976-09-16 1977-08-30 The United States Of America As Represented By The Department Of Health, Education And Welfare Method of producing thebaine from codeine and oripavine from morphine
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4272540A (en) * 1979-04-24 1981-06-09 Sisa, Incorporated 14-Methoxymorphinan-6-one compounds and therapeutic methods of treating pain and drug dependence with them
US4370333A (en) * 1981-06-29 1983-01-25 Sisa, Incorporated 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it
US4795813A (en) * 1981-08-17 1989-01-03 The Florida Board Of Regents On Behalf Of The Florida State University Synthesis of derivatives of codeine and other 3-O-alkylmorphines
US4639520A (en) * 1984-03-27 1987-01-27 Mallinckrodt, Inc. Preparation of 14-hydroxy-N-ethoxy-carbonyl-norcodeinone
US5112975A (en) 1984-03-27 1992-05-12 Mallinckrodt Specialty Chemicals Company Preparation of noroxymorphone from morphine
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4810699A (en) * 1987-02-20 1989-03-07 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano[3,4,-b]indole-1-acetic acids, pharmaceutical compositions containing them, and methods for treating inflammatory conditions and for analgesic purposes using them
US4810669A (en) * 1987-07-07 1989-03-07 Oki Electric Industry Co., Ltd. Method of fabricating a semiconductor device
DE3812567A1 (de) 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
HU208633B (en) 1991-02-04 1993-12-28 Alkaloida Vegyeszeti Gyar Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
JP3433871B2 (ja) * 1996-01-26 2003-08-04 株式会社デンソー 集積化半導体歪みセンサ及びその製造方法
DE09003265T1 (de) 1996-06-26 2010-04-29 Board of Regents, The University of Texas System, Austin Extrudierbare pharmazeutische Schmelzklebstoffformulierung
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
ES2121554B1 (es) * 1996-12-23 1999-06-16 Univ Santiago Compostela Procedimiento de obtencion de 14-hidroximofinonas mediante fotooxidac ion de alcaloides morfinicos con sistema alcoxidienico en el anillo c.
GB9713703D0 (en) * 1997-06-30 1997-09-03 Johnson Matthey Plc Preparation of opiates
GB9717629D0 (en) 1997-08-21 1997-10-22 Johnson Matthey Plc Removal of residual organic solvents
US6710223B1 (en) 1997-09-10 2004-03-23 The Procter & Gamble Company Method for improving skin condition
GB9805516D0 (en) 1998-03-17 1998-05-13 Johnson Matthey Plc Preparation of opiates
JP4447168B2 (ja) * 1998-10-14 2010-04-07 オーミック・アクチボラゲット 原盤及び該原盤の製造方法
US6177567B1 (en) * 1999-10-15 2001-01-23 Boehringer Ingelheim Chemicals, Inc. Method for preparing oxycodone
US6284769B1 (en) * 1999-12-03 2001-09-04 The Board Of Trustees Of The University Of Illinois Nonpeptide kappa opioid receptor antagonists
US6133132A (en) * 2000-01-20 2000-10-17 Advanced Micro Devices, Inc. Method for controlling transistor spacer width
AU776904B2 (en) * 2000-02-08 2004-09-23 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP1285902A4 (en) 2000-05-29 2007-04-18 Shionogi & Co TRITIUM MARKING PROCESS
US7200357B2 (en) * 2000-10-20 2007-04-03 Universal Electronics Inc. Automotive storage and playback device and method for using the same
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
EP1399161B1 (en) * 2001-06-05 2011-04-20 Control Delivery Systems Sustained-release analgesic compounds
CA2449519A1 (en) 2001-06-08 2002-12-19 Endo Pharmaceuticals, Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
WO2003007802A2 (en) 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
AU2003235678A1 (en) * 2002-01-15 2003-07-30 Aerogen, Inc. Systems and methods for clearing aerosols from the effective anatomic dead space
AU2003220551A1 (en) * 2002-03-26 2003-10-13 Euro-Celtique S.A. Sustained-release gel coated compositions
PL373031A1 (en) * 2002-04-29 2005-08-08 Alza Corporation Methods and dosage forms for controlled delivery of oxycodone
JP3811491B2 (ja) * 2002-05-27 2006-08-23 株式会社エヌ・ティ・ティ・ドコモ 移動通信システム、送信局、受信局、中継局および通信経路決定方法
BR0304960A (pt) 2002-05-31 2005-01-04 Alza Corp Formas de dosagem e composições para liberação osmótica de dosagens variáveis de oxicodona
US7399488B2 (en) * 2002-07-05 2008-07-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US20040058946A1 (en) * 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
WO2004016618A1 (en) * 2002-08-15 2004-02-26 Noramco, Inc. Oxycodone-hydrochloride polymorhs
US7192966B2 (en) 2002-11-15 2007-03-20 Branded Products For The Future Pharmaceutical composition
MXPA05005781A (es) * 2002-11-29 2005-12-12 Forest Laboratories Combinacion de ibuprofeno y oxicodona para alivio de dolor agudo.
FR2850576B1 (fr) 2003-02-05 2007-03-23 Ethypharm Sa Composition comprenant un melange de principes actifs, et procede de preparation
MXPA05009757A (es) 2003-03-13 2005-12-05 Controlled Chemicals Inc Conjugados de oxicodona con menor potencial de abuso y duracion de accion extendida.
US6864370B1 (en) * 2003-06-05 2005-03-08 Zhaiwei Lin Process for manufacturing oxycodone
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070172958A1 (en) * 2004-03-30 2007-07-26 Euro-Celtique S.A. Methods for detecting 14-hydroxy codeinone and codeinone
TWI483944B (zh) 2004-03-30 2015-05-11 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
US20050226929A1 (en) 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
JP5329083B2 (ja) 2004-06-25 2013-10-30 テッセラ，インコーポレイテッド ポストおよびパッドを有する部品
GB0421149D0 (en) 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
ME01594B (me) 2005-03-04 2014-09-20 Euro Celtique Sa Postupak smanjenja alfa, beta nezasićenih ketona u opioidnim kompozicijama
AU2006259780B2 (en) 2005-06-16 2012-04-12 SpecGx LLC A synthetic route to 14-hydroxyl opiates through 1-halo-thebaine or analogs
US7875623B2 (en) 2005-11-22 2011-01-25 Controlled Chemicals, Inc. Process for reducing contaminating Michael acceptor levels in oxycodone and other compositions
US20070117826A1 (en) 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
CN101395159A (zh) 2006-03-02 2009-03-25 马林克罗特公司 制备含有低含量α,β-不饱和酮化合物的吗啡烷-6-酮产物的方法
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US7906647B2 (en) * 2006-12-04 2011-03-15 Noramco, Inc. Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone
AU2007329451B2 (en) 2006-12-04 2012-08-30 Noramco, Llc Process for reducing impurities in oxycodone base
GB2450691A (en) 2007-07-02 2009-01-07 Alpharma Aps One-pot preparation of oxycodone from thebaine
CA2804101C (en) 2010-07-02 2021-01-19 Johnson Matthey Public Limited Company Process for the synthesis and purification of oxycodone
US9062062B1 (en) * 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride

Also Published As

Publication number Publication date
US20060173029A1 (en) 2006-08-03
US20160251365A1 (en) 2016-09-01
KR20130020962A (ko) 2013-03-04
US9073933B2 (en) 2015-07-07
US20160250204A1 (en) 2016-09-01
BRPI0508758B8 (pt) 2021-05-25
JP2007531756A (ja) 2007-11-08
TW201231469A (en) 2012-08-01
DK200700214U3 (da) 2008-02-08
HUE029913T2 (en) 2017-04-28
FIU20070284U0 (fi) 2007-07-04
RS51693B2 (sr) 2021-02-26
PT2316837T (pt) 2018-04-02
KR20120046309A (ko) 2012-05-09
PL1730151T3 (pl) 2011-08-31
US20210198268A1 (en) 2021-07-01
TWI365880B (en) 2012-06-11
US10696684B2 (en) 2020-06-30
US20100152449A1 (en) 2010-06-17
EP1730151B2 (en) 2020-09-16
FI7843U1 (fi) 2008-04-28
ES2535618T3 (es) 2015-05-13
US7674800B2 (en) 2010-03-09
US20160185788A1 (en) 2016-06-30
CA2774121C (en) 2016-02-16
KR20150046393A (ko) 2015-04-29
US20070117830A1 (en) 2007-05-24
NZ602862A (en) 2014-01-31
US11236098B2 (en) 2022-02-01
KR20090104145A (ko) 2009-10-05
CY1117841T1 (el) 2017-05-17
MY154985A (en) 2015-08-28
IL213888A0 (en) 2011-07-31
KR20180088505A (ko) 2018-08-03
DK2316837T3 (en) 2018-04-16
CN102887903B (zh) 2016-01-27
AR049012A1 (es) 2006-06-21
JP2015187134A (ja) 2015-10-29
PL2316837T3 (pl) 2018-07-31
JP2012072162A (ja) 2012-04-12
EP2316837A1 (en) 2011-05-04
ES2585576T3 (es) 2016-10-06
HK1155729A1 (zh) 2012-05-25
CA2913355A1 (en) 2005-10-20
PT1730151E (pt) 2011-06-01
US20070117829A1 (en) 2007-05-24
RS53891B1 (en) 2015-08-31
IL213890A (en) 2015-10-29
AT9952U1 (de) 2008-06-15
EP2314589A1 (en) 2011-04-27
HK1155728A1 (zh) 2012-05-25
RS51693B (en) 2011-10-31
DK1730151T3 (da) 2011-06-20
US7674799B2 (en) 2010-03-09
PE20050880A1 (es) 2005-11-16
IL241117A0 (en) 2015-11-30
EA200601520A1 (ru) 2007-02-27
US20160251364A1 (en) 2016-09-01
US20160176889A1 (en) 2016-06-23
ES2665287T3 (es) 2018-04-25
KR20200000499A (ko) 2020-01-02
IL241117B (en) 2020-06-30
MY143205A (en) 2011-03-31
JP2018184462A (ja) 2018-11-22
US20210094963A1 (en) 2021-04-01
US20160175299A1 (en) 2016-06-23
ES2566363T3 (es) 2016-04-12
HRP20150358T1 (hr) 2015-05-08
SI1730151T2 (sl) 2021-03-31
US20090227615A1 (en) 2009-09-10
JP2011157370A (ja) 2011-08-18
EP2311839A1 (en) 2011-04-20
LT2314589T (lt) 2023-06-12
SG170736A1 (en) 2011-05-30
PL2305683T3 (pl) 2015-07-31
US7683072B2 (en) 2010-03-23
US20160251363A1 (en) 2016-09-01
AU2009200335B2 (en) 2011-07-28
CN101812065B (zh) 2012-03-28
DK200700214U1 (da) 2007-11-23
JP5118223B2 (ja) 2013-01-16
MY172063A (en) 2019-11-13
CN102127086A (zh) 2011-07-20
CN101812065A (zh) 2010-08-25
KR20120106784A (ko) 2012-09-26
CN102887903A (zh) 2013-01-23
CA2774121A1 (en) 2005-10-20
HRP20110425T1 (en) 2011-07-31
US20160185789A1 (en) 2016-06-30
AP2006003738A0 (en) 2006-10-31
US7674798B2 (en) 2010-03-09
ME01299B (me) 2011-10-31
CA2557845A1 (en) 2005-10-20
US20050222188A1 (en) 2005-10-06
DK1730151T4 (da) 2020-10-19
ES2938727T3 (es) 2023-04-14
US20070117831A1 (en) 2007-05-24
EP2305683A1 (en) 2011-04-06
CY1117228T1 (el) 2017-04-05
KR20100069719A (ko) 2010-06-24
KR100930730B1 (ko) 2009-12-09
US20160175300A1 (en) 2016-06-23
US20160176888A1 (en) 2016-06-23
US20110207762A1 (en) 2011-08-25
US20200087316A1 (en) 2020-03-19
US9522919B2 (en) 2016-12-20
SI2305683T1 (sl) 2015-04-30
US7129248B2 (en) 2006-10-31
IL213891A0 (en) 2011-07-31
EP2426132B1 (en) 2016-01-13
ME02482B (me) 2017-02-20
MX363228B (es) 2019-03-15
RS54941B1 (sr) 2016-11-30
US9777011B2 (en) 2017-10-03
IL235298A (en) 2016-11-30
CY1120171T1 (el) 2018-12-12
SI1730151T1 (sl) 2011-06-30
NO20064935L (no) 2006-12-18
SG10201406658VA (en) 2014-12-30
US10689389B2 (en) 2020-06-23
JP4912294B2 (ja) 2012-04-11
NO337669B1 (no) 2016-05-30
DK2426132T3 (en) 2016-04-04
AU2005230826A1 (en) 2005-10-20
US20160175298A1 (en) 2016-06-23
ECSP066953A (es) 2006-12-20
MX2020008878A (es) 2020-11-09
US20150265597A1 (en) 2015-09-24
US20160185790A1 (en) 2016-06-30
KR101200700B1 (ko) 2012-11-13
CY1111487T1 (el) 2015-08-05
IL213889A (en) 2012-06-28
KR20110110377A (ko) 2011-10-06
EP2319846A1 (en) 2011-05-11
US20150265598A1 (en) 2015-09-24
EP2305683B2 (en) 2024-09-11
AU2005230826B2 (en) 2008-11-06
KR20140021716A (ko) 2014-02-20
TW201509943A (zh) 2015-03-16
US10407434B2 (en) 2019-09-10
KR20070022033A (ko) 2007-02-23
US20230159548A1 (en) 2023-05-25
US20180022754A1 (en) 2018-01-25
US20190161492A1 (en) 2019-05-30
US8822687B2 (en) 2014-09-02
PT2319846T (pt) 2016-08-12
KR100993911B1 (ko) 2010-11-11
IL178038A0 (en) 2006-12-31
SI2316837T1 (en) 2018-05-31
DE202005021371U1 (de) 2007-10-25
ES2362282T3 (es) 2011-06-30
JP6503392B2 (ja) 2019-04-17
CN102838607B (zh) 2016-08-03
PT2426132E (pt) 2016-03-31
EP1730151B1 (en) 2011-03-09
ES2362282T5 (es) 2021-06-24
US20130005977A1 (en) 2013-01-03
TWI483944B (zh) 2015-05-11
AU2005230826C1 (en) 2014-10-16
HRP20160223T1 (hr) 2016-03-25
IL214050A (en) 2013-09-30
CY1116327T1 (el) 2017-02-08
DK2305683T3 (en) 2015-04-07
CR8593A (es) 2007-07-19
EP2314589B1 (en) 2022-12-28
SI2319846T1 (sl) 2016-08-31
HUE036451T2 (hu) 2018-07-30
JP5543991B2 (ja) 2014-07-09
AU2009200335A1 (en) 2009-02-26
NZ549430A (en) 2010-05-28
JP2017125052A (ja) 2017-07-20
US20200062772A1 (en) 2020-02-27
EP2305683B1 (en) 2015-01-28
PL2319846T3 (pl) 2016-12-30
PL2426132T3 (pl) 2016-06-30
JP2012188439A (ja) 2012-10-04
AP2232A (en) 2011-05-04
CN102127086B (zh) 2013-11-27
MA28492B1 (fr) 2007-03-01
SI2426132T1 (sl) 2016-04-29
US11384091B2 (en) 2022-07-12
BRPI0508758B1 (pt) 2018-10-09
US20150258086A1 (en) 2015-09-17
IL213889A0 (en) 2011-07-31
TW200540177A (en) 2005-12-16
US20160250205A1 (en) 2016-09-01
CR20110376A (es) 2011-09-19
EP2319846B1 (en) 2016-05-04
KR101410141B1 (ko) 2014-06-25
HRP20180407T1 (hr) 2018-04-20
KR20140133615A (ko) 2014-11-19
RS54598B1 (en) 2016-08-31
LT2316837T (lt) 2018-04-10
HK1098745A1 (en) 2007-07-27
ME03068B (me) 2019-01-20
US20160264588A1 (en) 2016-09-15
EP2305683B8 (en) 2015-03-04
ME02411B (me) 2016-09-20
IL213890A0 (en) 2011-07-31
EA013208B1 (ru) 2010-04-30
CN102838607A (zh) 2012-12-26
DK2319846T3 (en) 2016-08-15
HRP20110425T4 (hr) 2020-11-27
EP1730151A4 (en) 2007-05-23
EP1730151A1 (en) 2006-12-13
PL1730151T5 (pl) 2023-09-18
CN1960994B (zh) 2012-09-05
US10259819B2 (en) 2019-04-16
IL214050A0 (en) 2011-08-31
EP2426132A1 (en) 2012-03-07
WO2005097801A1 (en) 2005-10-20
BRPI0508758A (pt) 2007-08-28
CN1960994A (zh) 2007-05-09
HUE028233T2 (en) 2016-12-28
HRP20160885T1 (hr) 2016-09-23
IL178038A (en) 2015-10-29
CA2557845C (en) 2013-10-01
US12060361B2 (en) 2024-08-13
RS57000B1 (sr) 2018-05-31
PT2305683E (pt) 2015-05-18
ZA200607181B (en) 2007-11-28
JP5378486B2 (ja) 2013-12-25
CA2913355C (en) 2021-04-20
US20070179169A1 (en) 2007-08-02
EP2316837B1 (en) 2018-01-10
NZ601326A (en) 2013-10-25
JP2014139205A (ja) 2014-07-31
ATE501150T1 (de) 2011-03-15
DE602005026786D1 (de) 2011-04-21
US20230365578A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
MY172063A (en) Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
WO2008070656A3 (en) Process for reducing impurities in oxycodone base
TW200639161A (en) Process for the purification of duloxetine hydrochloride
GEP20094655B (en) Process for preparing oxycodone hydrochloride having less than 25 pm 14-hydroxycodeinone
WO2009009292A3 (en) Crystalline forms of naltrexone methobromide
UA67007A (en) Cyproteron as a remedy for treating opiate addiction